Chinese Medicine Regulates DNA Methylation to Treat Haematological Malignancies: A New Paradigm of "State-Target Medicine".
10.1007/s11655-021-3316-7
- Author:
Feng-Lin SHEN
1
;
Yan-Na ZHAO
1
;
Xiao-Ling YU
1
;
Bo-Lin WANG
1
;
Xiao-Long WU
1
;
Gao-Chen LAN
1
;
Rui-Lan GAO
2
,
3
Author Information
1. Institute of Hematology Research, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310006, China.
2. Institute of Hematology Research, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310006, China. gaoruilan@
3. com.
- Publication Type:Journal Article
- Keywords:
Chinese medicine;
DNA methylation;
haematological malignancies;
state-target medicine
- MeSH:
DNA Methylation/genetics*;
Drugs, Chinese Herbal;
Hematologic Neoplasms/genetics*;
Humans;
Materia Medica;
Medicine, Chinese Traditional
- From:
Chinese journal of integrative medicine
2022;28(6):560-566
- CountryChina
- Language:English
-
Abstract:
Aberrant regulation of DNA methylation plays a crucial causative role in haematological malignancies (HMs). Targeted therapy, aiming for DNA methylation, is an effective mainstay of modern medicine; however, many issues remain to be addressed. The progress of epigenetic studies and the proposed theory of "state-target medicine" have provided conditions to form a new treatment paradigm that combines the "body state adjustment" of CM with targeted therapy. We discussed the correlation between Chinese medicine (CM) syndromes/states and DNA methylation in this paper. Additionally, the latest research findings on the intervention and regulation of DNA methylation in HMs, including the core targets, therapy status, CM compounds and active components of the Chinese materia medica were concisely summarized to establish a theoretical foundation of "state-target synchronous conditioning" pattern of integrative medicine for HMs, simultaneously leading a new perspective in clinical diagnosis and therapy.
